Quantcast
Home > Quotes > NVRO

Nevro Corp. Common Stock (NVRO) Quote & Summary Data

NVRO 
$85.02
*  
2.02
2.43%
Get NVRO Alerts
*Delayed - data as of Aug. 21, 2019  -  Find a broker to begin trading NVRO now
Exchange:NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
70
Today's High / Low
$ 85.35 / $ 82.36
Share Volume
317,261
90 Day Avg. Daily Volume
471,744
Previous Close
$ 83
52 Week High / Low
$ 83.57 / $ 34.75
Market Cap
2,625,868,376
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -3.05
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.73

Intraday Chart

Shares Traded

Share Volume:
317,261
90 Day Avg. Daily Volume:
471,744

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.05

Trading Range

The current last sale of $85.02

Intraday Last 52 Weeks
High: $ 85.35 $ 83.57
 Low: $ 82.36 $ 34.75

ETFs with NVRO as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
2.08% SPDR S&P Health Care Equipment (XHE) +0.51 (0.64%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. We have developed and commercialized the Senza┬« spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Our proprietary paresthesia-free HF10TM therapy, delivered by our Senza system, was demonstrated in our SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. Our SENZA-RCT study, along with our European studies, represents what we believe is the most robust body of clinical evidence for any SCS therapy.  ... More ...  



Risk Grade

Where does NVRO fit in the risk graph?


Risk Grade Scale



Consensus Recommendation

Analyst Info